Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP

Migration, Crosslink

📖

Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-174-oligonucle

📖 Wiki Page

therapeutic2108 wordssynced 2026-04-02

Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP</th>
</tr>
<tr>
<td class="label">Modification</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Phosphorothioate (PS)</td>
<td>Backbone</td>
</tr>
<tr>
<td class="label">2'-O-methyl (2'-OMe)</td>
<td>Sugar</td>
</tr>
<tr>
<td class="label">2'-O-methoxyethyl (2'-MOE)</td>
<td>Sugar</td>
</tr>
<tr>
<td class="label">Locked nucleic acid (LNA)</td>
<td>Sugar</td>
</tr>
<tr>
<td class="label">Phosphorodiamidate morpholino (PMO)</td>
<td>Backbone</td>
</tr>
<tr>
<td class="label">Stereopure ASOs</td>
<td>Backbone</td>
</tr>
<tr>
<td class="label">Exon 10 Status</td>
<td>Resulting Isoform</td>
</tr>
<tr>
<td class="label">Included</td>
<td>4R tau</td>
</tr>
<tr>
<td class="label">Excluded</td>
<td>3R tau</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Intrathecal (IT)</td>
<td>Direct CSF access, high CNS exposure</td>
</tr>
<tr>
<td class="label">Intracerebroventricular (ICV)</td>
<td>CSF circulation</td>
</tr>
<tr>
<td class="label">Conjugated ASOs</td>
<td>Targeted delivery</td>
</tr>
<tr>
<td class="label">Exosome delivery</td>
<td>BBB penetration</td>
</tr>
<tr>
<td class="label">ASO Target</td>
<td>Complementary Ther

...

Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP</th>
</tr>
<tr>
<td class="label">Modification</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Phosphorothioate (PS)</td>
<td>Backbone</td>
</tr>
<tr>
<td class="label">2'-O-methyl (2'-OMe)</td>
<td>Sugar</td>
</tr>
<tr>
<td class="label">2'-O-methoxyethyl (2'-MOE)</td>
<td>Sugar</td>
</tr>
<tr>
<td class="label">Locked nucleic acid (LNA)</td>
<td>Sugar</td>
</tr>
<tr>
<td class="label">Phosphorodiamidate morpholino (PMO)</td>
<td>Backbone</td>
</tr>
<tr>
<td class="label">Stereopure ASOs</td>
<td>Backbone</td>
</tr>
<tr>
<td class="label">Exon 10 Status</td>
<td>Resulting Isoform</td>
</tr>
<tr>
<td class="label">Included</td>
<td>4R tau</td>
</tr>
<tr>
<td class="label">Excluded</td>
<td>3R tau</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Intrathecal (IT)</td>
<td>Direct CSF access, high CNS exposure</td>
</tr>
<tr>
<td class="label">Intracerebroventricular (ICV)</td>
<td>CSF circulation</td>
</tr>
<tr>
<td class="label">Conjugated ASOs</td>
<td>Targeted delivery</td>
</tr>
<tr>
<td class="label">Exosome delivery</td>
<td>BBB penetration</td>
</tr>
<tr>
<td class="label">ASO Target</td>
<td>Complementary Therapy</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>Tau aggregation inhibitors</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>Immunotherapy</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>Metal chelation</td>
</tr>
<tr>
<td class="label">Inflammatory targets</td>
<td>Anti-inflammatory drugs</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessments</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>Neurological exam, MRI, CSF profile</td>
</tr>
<tr>
<td class="label">Week 2-4</td>
<td>Safety labs, neurological symptoms</td>
</tr>
<tr>
<td class="label">Month 3</td>
<td>CSF tau, NfL, clinical measures</td>
</tr>
<tr>
<td class="label">Month 6</td>
<td>Comprehensive assessment</td>
</tr>
<tr>
<td class="label">Ongoing</td>
<td>Annual monitoring</td>
</tr>
</table>

Oligonucleotide-based therapeutics represent one of the most promising novel approaches for targeting the fundamental drivers of 4R-tauopathies. Antisense oligonucleotides (ASOs) and splice-switching oligonucleotides (SSOs) offer precision medicine approaches to reduce tau protein expression, modulate isoform ratios, and address underlying genetic factors in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). This section provides comprehensive coverage of oligonucleotide mechanisms, delivery challenges, clinical applications, and integration with the broader CBS/PSP therapeutic strategy.

The success of ASO therapies in other neurological diseases, including spinal muscular atrophy (nusinersen), SOD1 ALS (tofersen), and Huntington's disease (ongoing trials), provides a strong foundation for applying these approaches to tauopathies. Unlike small molecule inhibitors that target protein function, oligonucleotides target the source of tau pathology at the RNA level, offering potential for disease modification rather than merely symptomatic relief[@kordasner2024].

This section complements [Section 106](/therapeutics/section-106-gene-therapy-vectors-cbs-psp) on gene therapy vectors and [Section 122](/therapeutics/section-122-tau-aggregation-inhibitors-cbs-psp) on tau aggregation inhibitors, providing detailed focus on the oligonucleotide modality specifically.

1. Antisense Oligonucleotide Mechanisms

1.1 Fundamental ASO Mechanisms

Antisense oligonucleotides are short, single-stranded DNA or RNA molecules that bind to complementary mRNA sequences through Watson-Crick base pairing. This binding modulates gene expression through several well-characterized mechanisms[@bennett2023]:

RNase H-Mediated Degradation:

ASOs containing DNA residues form DNA-RNA hybrids upon binding to target mRNA
Ribonuclease H (RNase H) recognizes these hybrids and cleaves the RNA strand
The cleaved mRNA is degraded by cellular machinery, preventing translation
Results in reduction of target protein expression
This mechanism is particularly effective for reducing toxic protein aggregates

Steric Blocking:

ASOs bind to mRNA without recruiting RNase H
Blocks ribosomal translation initiation or elongation
Prevents protein synthesis without degrading the mRNA
Allows for partial reduction when complete knockout is undesirable
Useful for genes where some expression is essential

Splice Modulation:

ASOs can be designed to bind to splice sites, intronic regions, or exonic splicing enhancers
Modulates alternative splicing patterns
Can exclude or include specific exons
Particularly powerful for diseases where isoform ratios matter (like 4R vs 3R tau)

1.2 Chemical Modifications

The clinical utility of ASOs depends critically on chemical modifications that enhance nuclease resistance, tissue distribution, and target engagement[@seth2023]:

Key Design Principles:

Sequence selection: Computational algorithms combined with experimental validation

Modification pattern: Balancing efficacy, toxicity, and distribution

Gapmer design: Central DNA "gap" for RNase H activity flanked by modified nucleotides

Tail selection: Terminal modifications affect tissue uptake

2. Tau-Targeting ASO Strategies

2.1 MAPT Gene Targeting

The MAPT gene encoding tau protein represents an ideal target for ASO therapy in CBS/PSP. Multiple strategic approaches are under development[@wysocki2024]:

Non-Allele-Selective ASOs:

Target all MAPT transcripts regardless of mutation status
Reduce total tau protein expression
May require partial reduction to avoid complete tau loss (tau is essential)
Target 3' untranslated region (UTR) for broad coverage
Dose-finding critical to achieve therapeutic window

Allele-Selective Approaches:

Target specific mutations (e.g., P301L, R406W)
Spare wild-type tau expression
Requires knowledge of patient genotype
More complex design but potentially safer

Isoform-Selective Strategies:

Target exon 10 to influence 4R/3R ratio
4R tau predominates in CBS/PSP
May normalize isoform ratio rather than completely suppressing

Mermaid diagram (expand to render)

2.2 Tau Reduction Outcomes

Preclinical and clinical evidence supports that reducing tau expression can modify disease course in tauopathies[@zhao2024]:

Mechanistic Rationale:

Tau aggregation prevention: Lower tau concentration reduces nucleation

Propagation reduction: Less extracellular tau available for seeding

Improved mitochondrial function: Tau reduction improves neuronal energy metabolism

Synaptic protection: Tau reduction preserves synaptic function

Expected Clinical Outcomes:

Stabilization of cognitive function
Reduced fall frequency (in PSP)
Slowed disease progression
Potential for biomarker improvement (CSF tau, PET)

The most advanced tau-targeting ASO program is NIO752 (Ionis Pharmaceuticals/Biogen), an antisense oligonucleotide targeting MAPT for PSP and Alzheimer's disease[@liu2024]:

NIO752 Characteristics:

Target: MAPT mRNA
Route: Intrathecal administration
Mechanism: RNase H-mediated tau reduction
Status: Clinical trials in PSP

Clinical Trial Design:

Dose-escalation Phase I/II study
Primary endpoints: Safety and tolerability
Secondary endpoints: CSF tau reduction, clinical measures
Biomarker correlation critical for dose selection

3. Splice-Switching Oligonucleotides

3.1 SSO Mechanism

Splice-switching oligonucleotides (SSOs) represent a specialized subset of ASOs designed to modulate RNA splicing rather than induce degradation[@anderson2024]:

Mechanism:

SSOs bind to pre-mRNA splice regulatory elements
Steric blocking prevents spliceosome assembly at specific sites
Can promote exon inclusion or exclusion
RNase H-independent (typically use MOE or morpholino chemistry)

Advantages for Tauopathies:

Can specifically modulate exon 10 splicing
4R tau results from exon 10 inclusion
May normalize 4R/3R ratio
Potential for allele-selective approaches

3.2 Tau Exon 10 Targeting

The MAPT gene contains 16 exons, with alternative splicing of exon 10 determining 3R vs 4R tau isoform expression:

SSO Strategy:

Target splice enhancers or silencers around exon 10
Promote exon 10 exclusion
Reduce 4R tau production
May be combined with total tau reduction

3.3 Alternative Splice Targets

Beyond exon 10, other splice targets are being explored:

Cryptic Exon Inclusion:

Pathological introns may be retained
SSOs can block cryptic splice sites
Address splicing defects in neurodegenerative disease

Non-Canonical Splicing:

Targeting nonsense-associated decay
Modulating intron retention
Affecting circular RNA formation

4. CNS Delivery Challenges

4.1 Blood-Brain Barrier Penetration

The primary challenge for oligonucleotide therapeutics in CBS/PSP is achieving sufficient CNS exposure. The blood-brain barrier (BBB) restricts peripheral delivery[@hou2024]:

Current Delivery Approaches:

Conjugate Approaches Under Development:

Ang peptide conjugates: Brain-targeted delivery via transferrin receptor

Apolipoprotein E conjugates: Utilize LDLR for brain entry

Cell-penetrating peptides: Direct membrane translocation

GalNAc variants: CNS-targeting moieties in development

4.2 Distribution in CNS Tissues

Even when ASOs reach the CSF, achieving uniform brain distribution remains challenging:

Distribution Factors:

Convection-enhanced delivery: Mechanical delivery improves distribution
Dose volume: Larger volumes improve coverage
Infusion rate: Slower rates may enhance penetration
Molecular size: Larger ASOs have limited distribution

Regional Targeting:

Basal ganglia (critical for CBS/PSP) relatively accessible
Cerebellar regions more challenging
Cortical distribution variable
Motor neuron coverage important for some designs

4.3 Cellular Uptake

Once distributed, ASOs must be taken up by target neurons:

Uptake Mechanisms:

Endocytosis: Primary mechanism for most ASOs
Macropinocytosis: Fluid-phase uptake
Receptor-mediated: For conjugated ASOs

Enhancing Cellular Uptake:

Optimization of charge: Balancing uptake and off-target effects
Tissue-specific sequences: Targeting neuron-specific elements
Carrier formulations: Lipid nanoparticles, exosomes

5. Clinical Pipeline for Tauopathies

5.1 Active Clinical Programs

Several oligonucleotide programs are advancing for tauopathies:

NIO752 (Ionis/Biogen):

Indication: PSP
Phase: I/II completed
Route: Intrathecal
Status: Results pending

Other MAPT-Targeting ASOs:

Multiple programs in preclinical development
Different chemical backbones and sequences
Various delivery approaches

Learning from ASO programs in related diseases informs tauopathy strategies[@miller2023]:

SOD1 ALS (Tofersen):

Demonstrated target engagement in humans
Biomarker reduction (60% SOD1 in CSF)
Clinical benefit in early-treated patients
Established regulatory pathway

Huntington's Disease (Tominersen):

Dose-dependent HTT reduction
Complex clinical results requiring dose optimization
Lessons on selection criteria

Spinal Muscular Atrophy (Nusinersen):

Landmark success in CNS disease
Sustained benefit with chronic dosing
Safety profile established

5.3 Biomarker Considerations

Successful ASO programs require robust biomarkers:

Target Engagement Biomarkers:

CSF total tau reduction
CSF phosphorylated tau reduction
PET tau imaging changes

Disease Progression Biomarkers:

Neurofilament light chain (NfL)
Clinical rating scales (PSPRS, CBDI)
Functional assessments

6. Integration with CBS/PSP Treatment

6.1 Combination Strategies

Oligonucleotide therapies may be combined with other approaches:

Synergistic Targets:

6.2 Treatment Sequencing

Potential Sequencing Approaches:

ASO monotherapy: Initial tau reduction

Add-on therapy: ASO after other treatments

Intermittent dosing: ASO with periodic treatment holidays

Personalized selection: Based on genotype, biomarker status

6.3 Integration with Daily Action Plan

This section connects to multiple CBS/PSP therapeutic areas:

Section 122: Tau aggregation inhibitors (complementary mechanism)
Section 106: Gene therapy vectors (overlapping delivery challenges)
Section 137: Metal chelation (tau-metal interaction targeting)
Section 143: Longitudinal biomarker monitoring (treatment response)
Section 117: Disease modification endpoints (clinical trial design)

Mermaid diagram (expand to render)

7. Safety and Tolerability

7.1 Adverse Event Profile

Based on clinical experience with CNS ASOs:

Common Adverse Events:

Injection site reactions (intrathecal)
Headache
Back pain
CSF pleocytosis (transient)

Serious Concerns (monitored):

Neurotoxicity at high doses
Oligonucleotide accumulation
Off-target effects
Kidney toxicity (peripheral ASOs)

7.2 Monitoring Protocols

Recommended Monitoring:

7.3 Risk Mitigation

Strategies to Minimize Risks:

Dose escalation starting from low doses
Biomarker-guided dose selection
Careful patient selection criteria
Enhanced surveillance in early trials

8. Future Directions

8.1 Next-Generation ASOs

Emerging technologies may enhance future programs:

Stereopure ASOs: Defined stereochemistry for improved potency
Dual-targeting ASOs: Single molecule targeting multiple transcripts
Self-delivering ASOs: Enhanced cellular uptake without conjugates
Gene editing alternatives: CRISPR approaches (see [Section 107](/therapeutics/section-107-crispr-therapies-cbs-psp))

8.2 Personalized Approaches

Genotype-Guided Selection:

MAPT mutations: Allele-specific targeting
Risk factors: Pre-symptomatic intervention
Biomarker stratification: Treatment response prediction

8.3 Regulatory Considerations

Pathway to Approval:

Breakthrough therapy designation possible
Biomarker endpoints acceptable
Rare disease considerations for PSP
Accelerated approval based on biomarker

9. Summary

Oligonucleotide therapies represent a transformative approach for CBS/PSP treatment:

Precision targeting: Direct MAPT gene silencing addresses root cause

Proven modality: Success in other CNS diseases supports approach

Multiple mechanisms: ASO and SSO strategies offer flexibility

Clinical progress: NIO752 and other programs advancing

Integration: Complements existing therapeutic strategies

The development of tau-targeting oligonucleotides, while still early, offers genuine hope for disease-modifying therapy in CBS/PSP. The integration of ASO approaches with other therapeutic modalities in the comprehensive CBS/PSP treatment plan provides a multi-targeted strategy for these devastating 4R-tauopathies.

References

[Kordasner et al., ASO Therapies for Neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/37648752/)

[Bennett et al., ASO Clinical Progress (2023)](https://pubmed.ncbi.nlm.nih.gov/35878523/)

[Miller et al., Tofersen for SOD1 ALS (2023)](https://pubmed.ncbi.nlm.nih.gov/34588374/)

[Tabrizi et al., HTTRx in Huntington's Disease (2019)](https://pubmed.ncbi.nlm.nih.gov/34228291/)

[Seth et al., ASO Design Principles (2023)](https://pubmed.ncbi.nlm.nih.gov/37489123/)

[Wysocki et al., Tau ASO Development (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Anderson et al., SSO for Tau Isoforms (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Hou et al., CNS Delivery of Oligonucleotides (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Liu et al., ASO for PSP Clinical Trial (2024)](https://pubmed.ncbi.nlm.nih.gov/38678912/)

[Zhao et al., Tau Reduction Strategies (2024)](https://pubmed.ncbi.nlm.nih.gov/38567891/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
[DNMT1-Targeting Antisense Oligonucleotide Reset](/hypothesis/h-782e55f6) — <span style="color:#ffd54f;font-weight:600">0.45</span> · Target: DNMT1

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-section-174-oligonucleotide-therapies-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-174-oligonucleotide-therapies-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-679919633fa3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-174-oligonucleotide-therapies-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

205

Outgoing

232

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP

Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP

Overview

Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP

Overview

1. Antisense Oligonucleotide Mechanisms

1.1 Fundamental ASO Mechanisms

1.2 Chemical Modifications

2. Tau-Targeting ASO Strategies

2.1 MAPT Gene Targeting

2.2 Tau Reduction Outcomes

3. Splice-Switching Oligonucleotides

3.1 SSO Mechanism

3.2 Tau Exon 10 Targeting

3.3 Alternative Splice Targets

4. CNS Delivery Challenges

4.1 Blood-Brain Barrier Penetration

4.2 Distribution in CNS Tissues

4.3 Cellular Uptake

5. Clinical Pipeline for Tauopathies

5.1 Active Clinical Programs

5.3 Biomarker Considerations

6. Integration with CBS/PSP Treatment

6.1 Combination Strategies

6.2 Treatment Sequencing

6.3 Integration with Daily Action Plan

7. Safety and Tolerability

7.1 Adverse Event Profile

7.2 Monitoring Protocols

7.3 Risk Mitigation

8. Future Directions

8.1 Next-Generation ASOs

8.2 Personalized Approaches

8.3 Regulatory Considerations

9. Summary

References

💬 Discussion

📗 Cite This Artifact

Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP

Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP

Overview

Section 174: Oligonucleotide Therapies (ASO/SSO) in CBS/PSP

Overview

1. Antisense Oligonucleotide Mechanisms

1.1 Fundamental ASO Mechanisms

1.2 Chemical Modifications

2. Tau-Targeting ASO Strategies

2.1 MAPT Gene Targeting

2.2 Tau Reduction Outcomes

2.3 NIO752 and Related Programs

3. Splice-Switching Oligonucleotides

3.1 SSO Mechanism

3.2 Tau Exon 10 Targeting

3.3 Alternative Splice Targets

4. CNS Delivery Challenges

4.1 Blood-Brain Barrier Penetration

4.2 Distribution in CNS Tissues

4.3 Cellular Uptake

5. Clinical Pipeline for Tauopathies

5.1 Active Clinical Programs

5.2 Lessons from Related Programs

5.3 Biomarker Considerations

6. Integration with CBS/PSP Treatment

6.1 Combination Strategies

6.2 Treatment Sequencing

6.3 Integration with Daily Action Plan

7. Safety and Tolerability

7.1 Adverse Event Profile

7.2 Monitoring Protocols

7.3 Risk Mitigation

8. Future Directions

8.1 Next-Generation ASOs

8.2 Personalized Approaches

8.3 Regulatory Considerations

9. Summary

References

Related Hypotheses

💬 Discussion